An unambiguous and sensitive method based on gas chromatography-chemical ionization-mass spectrometry has been developed to quantitate L-phenylalanine mustard and has been applied to measure levels ...in plasma of five patients receiving 0.15 to 0.25 mg/kg (10 to 17 mg) of the drug p.o. Peak plasma levels of 50 to 190 ng/ml were found to occur between 0.7 and 2.3 hr after ingestion. The time for the plasma level to fall to one-half of the peak value varied from 0.6 to 3 hr, and very low levels (less than 2 ng/ml) were present by 24 hr.
Skin Cancer in Transplant Patients O'Brien, John C.; Kwa, Julie; Clifford, Yvette B. ...
Proceedings - Baylor University. Medical Center,
19/7/1/, Letnik:
12, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Skin cancer is the most prevalent carcinoma in the USA. To preventrejection, transplant patients are subjected to intense immunosuppression that cancauseseemingly banalskin lesions to become ...aggressive and life threatening. Patient and physician education is necessary to inform those who are intimately and peripherally involved of these dangers. Pretransplant skinexaminations and removal of premalignant and malignant lesions are recommended. Careful follow-up in the posttransplant period is necessary to diagnose cancersat an early, curablestage. Histologic control of resection margins is importantto confirm completeremoval. Recurrent and locally advanced primary lesions should be considered for treatment with Mohs micrographic surgery. Wediscuss the courses of 2 recent patients who required majorablative surgery and irradiation therapy due to inadequate initial treatment. Wealso presenta review of the currentliteratureon the etiology, incidence, and treatment of lesions in transplant patients.
Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant ...chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients with Stage 2 (node positive) breast cancer. Doses of C and F were 600 mg/m2 and E was 75 mg/m2. Moderate granulocytopenia (median count = 610/mm3) occurred on day 14 of the first 21 day treatment course and was the main toxicity encountered with treatment, although there were no episodes of granulocytopenic fever. Grade 3 or 4 vomiting occurred in 40% and significant alopecia in 30% of patients. Four patients experienced transient asymptomatic decreases in calculated radionuclide cardiac ejection fraction of greater than or equal to 10% but no signs or symptoms of cardiac failure were observed. If epirubicin proves to be less cardiotoxic than doxorubicin, this combination would merit further evaluation as potential adjuvant therapy for early breast cancer.
This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other ...well-defined prognostic factors including type of adjuvant treatment. Between 1988 and 1998, we studied 669 patients with invasive node-negative breast cancer up to 5 cm in size and low proliferative rate measured by flow cytometry to determine S-phase fraction (SPF) or by histochemistry (Ki67/MIB1). At a median follow-up of 53 months, 5-year DFS for the entire group was 94% and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95% DFS), tamoxifen (441 patients, 94% DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92% DFS). In a multivariate prognostic factor analysis, only tumor size was significant; 5-year DFS was 96% for T1N0 cancer versus 89% for T2N0 cancer (
P = 0.01). We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.
This article reviews a series of 30 patients with soft tissue sarcomas of the extremities treated preoperatively with radiation therapy and (in 28 patients) with doxorubicin at Baylor University ...Medical Center's Sammons Cancer Center in the 10-year interval from 1984 through 1993. The goal of therapy was limb preservation by using en bloc resection of the tumor without amputation or compromise of local tumor control. Limb preservation was accomplished in 27 of 30 patients (90%), and there were no local recurrences. The principal cause of death was metastatic disease, occurring in 10 of 30 patients (33%). The 5-year probability of disease-free survival was 100% for stage IIIA (5 patients) and 56% for stage IIIB (15 patients). Complications were seen in 9 of 30 patients (30%). Normal or mildly impaired function of the affected extremity was achieved in 60% of patients, moderately impaired but functional extremity was achieved in 25% of the patients, and 3 patients required amputation because of tumor extent.
Head and Neck Cancer Mennel, Robert G.; Senzer, Neil N.; Lieberman, Z. H. ...
Proceedings - Baylor University. Medical Center,
10/1/1990, 1990-10-00, Letnik:
3, Številka:
4
Journal Article
PDF
